AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7049592 — intervention group
Group type: EXPERIMENTAL
Intervention: Amcinonide ointment 0.1 percent twice a day
Number of subjects: 50
Study 7049592 — intervention group
Group type: COMPARATOR
Intervention: Fluocinonide ointment 0.05 percent three times a day
Number of subjects: 50
Study 31647691 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation help
Number of subjects: 0
Study 31647691 — intervention group
Group type: COMPARATOR
Intervention: Control group (no navigation help)
Number of subjects: 0
Study 30604559 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin + Standard of Care (SoC)
Number of subjects: 2666
Study 30604559 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 2666
Study 28468770 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (400,000 IU oral vitamin D3, with an additional 200,000 IU if serum 25(OH)D was <100 nmol/L after 4 weeks)
Number of subjects: 62
Study 28468770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 28468770 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 62
Study 26042485 — intervention group
Group type: EXPERIMENTAL
Intervention: BF Spiromax 160/4.5 μg
Number of subjects: 90
Study 26042485 — intervention group
Group type: COMPARATOR
Intervention: BF Turbohaler 200/6 μg
Number of subjects: 90
Study 26042485 — intervention group
Group type: EXPERIMENTAL
Intervention: BF Spiromax 320/9 μg
Number of subjects: 90
Study 26042485 — intervention group
Group type: COMPARATOR
Intervention: BF Turbohaler 400/12 μg
Number of subjects: 90
Study 26042485 — intervention group
Group type: EXPERIMENTAL
Intervention: BF Spiromax (±charcoal block)
Number of subjects: 90
Study 26042485 — intervention group
Group type: COMPARATOR
Intervention: BF Turbohaler (±charcoal block)
Number of subjects: 90
Study 23331053 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybuprocaine hydrochloride (oxybuprocaine HCl)
Number of subjects: 50
Study 23331053 — intervention group
Group type: EXPERIMENTAL
Intervention: Thera tears (carboxymethylcellulose sodium)
Number of subjects: 50
Study 23331053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21312329 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Collaborative
Number of subjects: 60
Study 21312329 — intervention group
Group type: COMPARATOR
Intervention: Toolkit
Number of subjects: 60
Study 21312329 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study 19124223 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse‐assisted symptom management (NASM)
Number of subjects: 354
Study 19124223 — intervention group
Group type: COMPARATOR
Intervention: Automated telephone symptom management (ATSM)
Number of subjects: 354
Study 17407625 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisacodyl (5-10 mg daily)
Number of subjects: 144
Study 17407625 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium picosulphate (5-10 mg daily)
Number of subjects: 144
Study 17407625 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 144
Study 17407625 — intervention group
Group type: COMPARATOR
Intervention: Bisacodyl
Number of subjects: 144
Study 17407625 — intervention group
Group type: COMPARATOR
Intervention: Sodium picosulphate
Number of subjects: 144
Study 14627358 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt supplement (227 grams of commercial yogurt for 8 days)
Number of subjects: 202
Study 14627358 — intervention group
Group type: COMPARATOR
Intervention: No yogurt supplement
Number of subjects: 202
Study 10862849 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocervical brushing
Number of subjects: 315
Study 10862849 — intervention group
Group type: COMPARATOR
Intervention: Endocervical curettage (ECC)
Number of subjects: 315
Study 10862849 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 315
Study 9202587 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient-echo high spatial resolution sequence with split acquisition open mouth views
Number of subjects: 0
Study 9202587 — intervention group
Group type: COMPARATOR
Intervention: Spin-echo sequences
Number of subjects: 0
Study 1527431 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (single oral 400-mg dose)
Number of subjects: 236
Study 1527431 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (single intramuscular 250-mg dose)
Number of subjects: 236
Study 2860181 — intervention group
Group type: COMPARATOR
Intervention: Saline lavage
Number of subjects: 53
Study 2860181 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine‐gluconate lavage
Number of subjects: 53
Study 2860181 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline lavage with instillation of povidone‐iodine
Number of subjects: 53
Study 30734043 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of pioglitazone (titrated to 45 mg daily)
Number of subjects: 2885
Study 30734043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2885
Study 27624791 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P10
Number of subjects: 154
Study 27624791 — intervention group
Group type: COMPARATOR
Intervention: RTX
Number of subjects: 154
Study 26364029 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrates, activated prothrombin complex concentrates, or recombinant activated factor VII
Number of subjects: 2
Study 26364029 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 2
Study 26364029 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 2
Study 23709257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovixan (mometasone furoate)
Number of subjects: 0
Study 23709257 — intervention group
Group type: COMPARATOR
Intervention: Elocon (mometasone furoate)
Number of subjects: 0
Study 20947533 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite score of protein-energy nutritional status (cPENS) based on albumin, BMI, creatinine, and normalized protein nitrogen appearance (nPNA)
Number of subjects: 560
Study 20947533 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual parameters of cPENS (albumin and creatinine)
Number of subjects: 560
Study 19804705 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradaxa®
Number of subjects: 1000
Study 19804705 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 1000
Study 17536076 — intervention group
Group type: COMPARATOR
Intervention: Normoglycemia
Number of subjects: 700
Study 17536076 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated impaired glucose tolerance (IGT)
Number of subjects: 700
Study 17536076 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated impaired fasting glucose (IFG)
Number of subjects: 700
Study 17536076 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IFG-IGT
Number of subjects: 700
Study 15291683 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (6 mg/day)
Number of subjects: 78
Study 15291683 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (20 mg/day)
Number of subjects: 78
Study 15291683 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone and Haloperidol
Number of subjects: 78
Study 15291683 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum IL‐2 or IL‐8 concentrations
Number of subjects: 78
Study 11437041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg b.i.d.) with ursodeoxycholic acid (250 mg t.i.d.)
Number of subjects: 52
Study 11437041 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid alone
Number of subjects: 52
Study 10489084 — intervention group
Group type: EXPERIMENTAL
Intervention: Paradoxical intention included in treatment program
Number of subjects: 0
Study 10489084 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment program without paradoxical intention
Number of subjects: 0
Study 7886722 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler detection of microembolic signals by human observers
Number of subjects: 73
Study 7886722 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronal network for automated embolus detection
Number of subjects: 73
Study 7886722 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat examinations of the same patient
Number of subjects: 73
Study 7886722 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term monitoring of microembolic signals
Number of subjects: 73
Study 7886722 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intrasubject variability assessment
Number of subjects: 73
Study 2224290 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmable hearing aid with eight separate settings
Number of subjects: 22
Study 2224290 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmable hearing aid
Number of subjects: 22
Study 2224290 — intervention group
Group type: COMPARATOR
Intervention: Personal hearing aids fitted according to NAL recommendations
Number of subjects: 22
Study 282097 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct intra-arterial blood pressure measurement
Number of subjects: 40
Study 282097 — intervention group
Group type: COMPARATOR
Intervention: Indirect blood pressure measurement (using regular sized adult cuff and thigh cuff)
Number of subjects: 40
Study 282097 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudohypertension (indirect diastolic greater than 100 mmHg, direct diastolic greater than 90 mmHg)
Number of subjects: 40
Study 282097 — intervention group
Group type: EXPERIMENTAL
Intervention: Errors in indirect measurement of blood pressure
Number of subjects: 40
Study 282097 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct intra-arterial measurement
Number of subjects: 40
Study 31293100 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail (AO)
Number of subjects: 30
Study 31293100 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR)
Number of subjects: 30
Study 31293100 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 30
Study 31293100 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 30
Study 27566854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh corneal graft carrier
Number of subjects: 37
Study 27566854 — intervention group
Group type: COMPARATOR
Intervention: Frozen corneal graft carrier
Number of subjects: 37
Study 24846662 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mM valine (1.5 mmol/kg BW)
Number of subjects: 6
Study 24846662 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 6
Study 23542532 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink
Number of subjects: 14
Study 23542532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 21716064 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate treatment for 12 weeks
Number of subjects: 23
Study 21716064 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 23
Study 21716064 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate treatment
Number of subjects: 23
Study 21716064 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 23
Study 19734379 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (10 sessions) plus self-care advice
Number of subjects: 267
Study 19734379 — intervention group
Group type: COMPARATOR
Intervention: Self-care advice only
Number of subjects: 267
Study 16409565 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine injection at lunch-time
Number of subjects: 23
Study 16409565 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine injection at dinner-time
Number of subjects: 23
Study 16409565 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine injection at bed-time
Number of subjects: 23
Study 12849652 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy with recurrent MI during index hospitalization
Number of subjects: 20101
Study 12849652 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention during index hospitalization
Number of subjects: 20101
Study 12849652 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 20101
Study 10512256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell salvage devices that do not wash salvaged blood in cardiac surgery
Number of subjects: 27
Study 10512256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell salvage devices that wash or do not wash salvaged blood in orthopedic surgery
Number of subjects: 27
Study 10512256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell salvage devices that do not wash salvaged blood in orthopedic surgery
Number of subjects: 27
Study 8730415 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood-flow (400 ml/min)
Number of subjects: 10
Study 8730415 — intervention group
Group type: COMPARATOR
Intervention: Low blood-flow (200 ml/min)
Number of subjects: 10
Study 2065846 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 12
Study 2065846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6313024 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged infusion of suxamethonium during halothane-nitrous oxide anaesthesia
Number of subjects: 40
Study 6313024 — intervention group
Group type: COMPARATOR
Intervention: Prolonged infusion of suxamethonium during fentanyl-nitrous oxide anaesthesia
Number of subjects: 40
Study 6313024 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine administration after stopping suxamethonium infusion
Number of subjects: 40
Study 3914838 — intervention group
Group type: COMPARATOR
Intervention: XRT alone
Number of subjects: 129
Study 3914838 — intervention group
Group type: EXPERIMENTAL
Intervention: XRT + chemotherapy (concomitant 5-FU during XRT and maintenance 5-FU + MeCCNU)
Number of subjects: 129
Study 3914838 — intervention group
Group type: EXPERIMENTAL
Intervention: XRT + chemotherapy
Number of subjects: 129
Study 31573608 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 52
Study 31573608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 28669071 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 0
Study 28669071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27622458 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent‐Child Interaction Therapy (PCIT)
Number of subjects: 81
Study 27622458 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 81
Study 25187584 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg daily for fifty days)
Number of subjects: 336
Study 25187584 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 336
Study 22854605 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release oral diacetylmorphine (DAM)
Number of subjects: 45
Study 22854605 — intervention group
Group type: COMPARATOR
Intervention: Slow-release oral morphine
Number of subjects: 45
Study 22854605 — intervention group
Group type: COMPARATOR
Intervention: Oral methadone
Number of subjects: 45
Study 19717246 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimenter-administered cocaine (0, 12.5, 25 and 50mg/70 kg, i.v.)
Number of subjects: 16
Study 19717246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine self-administration (0, 12.5 and 25mg/70 kg, i.v.)
Number of subjects: 16
Study 18435954 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with stenting
Number of subjects: 4
Study 18435954 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 4
Study 16932624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (combined with corticosteroids)
Number of subjects: 0
Study 16932624 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (for induction and maintenance of remission)
Number of subjects: 0
Study 16932624 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (for patients refractory to cyclophosphamide)
Number of subjects: 0
Study 16932624 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (combined with corticosteroids)
Number of subjects: 0
Study 14733345 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual aid (Group A)
Number of subjects: 38
Study 14733345 — intervention group
Group type: COMPARATOR
Intervention: Standard informed consent process (Group B)
Number of subjects: 38
Study 10643347 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral high-dose methylprednisolone (500 mg once daily for five days with a 10 days tapering period)
Number of subjects: 25
Study 10643347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8777648 — intervention group
Group type: EXPERIMENTAL
Intervention: ictal EEG data in lower frequency bands
Number of subjects: 44
Study 8777648 — intervention group
Group type: EXPERIMENTAL
Intervention: ictal EEG data in higher frequency bands
Number of subjects: 44
Study 8777648 — intervention group
Group type: EXPERIMENTAL
Intervention: ictal EEG data in three frequency bands
Number of subjects: 44
Study 2059131 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocker-soled shoes
Number of subjects: 0
Study 2059131 — intervention group
Group type: COMPARATOR
Intervention: Placebo shoe insert
Number of subjects: 0
Study 6832707 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating immune complexes detected by C1q binding assay
Number of subjects: 24
Study 6832707 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating immune complexes detected by Raji cell assay
Number of subjects: 24
Study 6832707 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating immune complexes detected by both methods
Number of subjects: 24
Study 6832707 — intervention group
Group type: COMPARATOR
Intervention: Levels of circulating immune complexes in PSC patients
Number of subjects: 24
Study 6832707 — intervention group
Group type: COMPARATOR
Intervention: Raji cell binding of sera from patients with extrahepatic biliary obstruction
Number of subjects: 24
Study 30799328 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-min holistic self-care program including modified Japanese Radio Taiso, gentle arm exercises, central lymphatic drainage, and skin care for 6 months
Number of subjects: 43
Study 30799328 — intervention group
Group type: COMPARATOR
Intervention: Usual care from hospitals
Number of subjects: 43
Study 29808950 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-elastic taping (NET)
Number of subjects: 50
Study 29808950 — intervention group
Group type: COMPARATOR
Intervention: Sham taping (Control)
Number of subjects: 50
Study 27153945 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Number of subjects: 72
Study 27153945 — intervention group
Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 72
Study 24927639 — intervention group
Group type: EXPERIMENTAL
Intervention: GRAZAX® (75,000 SQ-T/2,800 BAU, ALK, Denmark)
Number of subjects: 0
Study 24927639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24927639 — intervention group
Group type: EXPERIMENTAL
Intervention: GRAZAX®
Number of subjects: 0
Study 22056165 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating low pressure air mattress with multi-stage inflation and deflation cycle of the air cells
Number of subjects: 610
Study 22056165 — intervention group
Group type: COMPARATOR
Intervention: Alternating low pressure air mattress with standard single-stage inflation and deflation cycle of the air cells
Number of subjects: 610
Study 22056165 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 610
Study 20597561 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure wristbands applied at the P6 points
Number of subjects: 200
Study 20597561 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.2 mg/kg intravenously
Number of subjects: 200
Study 20597561 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.15 mg/kg intravenously
Number of subjects: 200
Study 20597561 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupressure, metoclopramide, or ondansetron)
Number of subjects: 200
Study 18395934 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/tetracaine patch
Number of subjects: 45
Study 18395934 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 45
Study 16022759 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified high-dose anthocyanoside oligomer (100 mg tablet comprising 85% anthocyanoside oligomer), administered twice daily for 4 weeks.
Number of subjects: 60
Study 16022759 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered twice daily for 4 weeks.
Number of subjects: 60
Study 12444837 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy (ORT)
Number of subjects: 34
Study 12444837 — intervention group
Group type: COMPARATOR
Intervention: Intravenous therapy
Number of subjects: 34
Study 11525345 — intervention group
Group type: EXPERIMENTAL
Intervention: JD plus skill training (ST)
Number of subjects: 237
Study 11525345 — intervention group
Group type: COMPARATOR
Intervention: JD plus mentoring (MEN)
Number of subjects: 237
Study 11525345 — intervention group
Group type: COMPARATOR
Intervention: JD (juvenile diversion)
Number of subjects: 237
Study 8711605 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.1%)
Number of subjects: 55
Study 8711605 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 55
Study 2058846 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone group (group N): 0.4 mg bolus followed by 5 micrograms.kg‐1.h‐1 infusion for 18 hours
Number of subjects: 40
Study 2058846 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (group P): normal saline instead of naloxone
Number of subjects: 40
Study 2058846 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone group (group N)
Number of subjects: 40
Study 2058846 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (group P)
Number of subjects: 40
Study 6600826 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 32
Study 6600826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32